SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation

Authors

  • Fieke W. Hoff Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Suleyman Y. Goksu 1Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Naveen Premnath Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Prapti A. Patel Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Ruth Ikpefan Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Gurbakhash Kaur Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Madhuri Vusirikala Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Taha Bat Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Weina Chen Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
  • Praveen Ramakrishnan Geethakumari Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Larry D., Jr Anderson Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Farrukh T. Awan Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Robert H. Collins Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Olga K. Weinberg Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
  • Alagarraju Muthukumar Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
  • Stephen S. Chung Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
  • Yazan F. Madanat Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX

DOI:

https://doi.org/10.5644/ama2006-124.399

Keywords:

SARS-CoV-2 Vaccination, Hematologic Malignancy, Antibody Response

Abstract

Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.

Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.

Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.

Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

Downloads

Download data is not yet available.

Downloads

Published

2023-06-11

How to Cite

Hoff, F. W. ., Goksu, S. Y. ., Premnath, N. ., Patel, P. A. ., Ikpefan, R. ., Kaur, G. ., … Madanat, Y. F. . (2023). SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation. Acta Medica Academica, 52(1), 30–36. https://doi.org/10.5644/ama2006-124.399

Issue

Section

Clinical Medicine

Similar Articles

<< < 1 2 3 4 > >> 

You may also start an advanced similarity search for this article.